To accelerate the development and commercialization of gene editing products in multiple therapeutic areas, the Company has formed, and intends to seek other opportunities to form, strategic alliances with collaborators who can augment its leadership in CRISPR/Cas9 therapeutic development. As of June 30, 2026 and December 31, 2025, the Company’s accounts receivable and contract liabilities were related to its collaboration with Regeneron Pharmaceuticals, Inc. (“Regeneron”).

The following table presents changes in the Company’s accounts receivable and contract liabilities (in thousands):


	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Six months ended June 30, 2026
Accounts receivable	$	9,468	$	15,501	$	(17,648	)	$	7,321
Contract liabilities - deferred revenue	$	7,290	$	-	$	(7,290	)	$	-

	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Six months ended June 30, 2025
Accounts receivable	$	8,517	$	20,439	$	(17,603	)	$	11,353
Contract liabilities - deferred revenue	$	38,917	$	1,079	$	(10,303	)	$	29,693

The Company has not incurred significant expenses to obtain collaboration agreements and costs to fulfill those contracts do not generate or enhance resources of the Company. As such, no costs to obtain or fulfill a contract have been capitalized in any period.

In April 2016, the Company entered into a license and collaboration agreement with Regeneron (as amended from time to time, the “2016 Regeneron Agreement”), which consisted of a product development component and a technology collaboration component. In October 2023, Regeneron exercised its one-time option to extend the term of the technology collaboration until April 2026, in exchange for a nonrefundable payment of $30.0 million that was paid in April 2024. The Company recognized $0.6 million and $5.8 million of collaboration revenue in the three and six months ended June 30, 2026, respectively, and $5.0 million and $10.1 million during the three and six months ended June 30, 2025, respectively, in the condensed consolidated statements of operations and comprehensive loss related to the 2016 Regeneron Agreement.

In 2018, the Company entered into a co-development and co-promotion (“Co/Co”) agreement with Regeneron for ATTR amyloidosis (the “ATTR Co/Co”). In May 2020, the Company entered into co-development and co-funding agreements for the treatment of hemophilia A and hemophilia B (the “Hemophilia A Co/Co” and the “Hemophilia B Co/Co” agreements). The Hemophilia B Co/Co ended in September 2024. The Company recognized $6.6 million and $15.0 million of collaboration revenue in the three and six months ended June 30, 2026, respectively, and $7.9 million and $14.9 million of collaboration revenue in the three and six months ended June 30, 2025, respectively, primarily representing payments due from Regeneron pursuant to the ATTR Co/Co agreement. The Company did not incur material costs related to the Hemophilia A Co/Co agreement during the three and six months ended June 30, 2026 and 2025. Since December 31, 2025, there have been no material changes to the key terms of the 2016 Regeneron Agreement, ATTR Co/Co or Hemophilia A Co/Co.

As of June 30, 2026 and December 31, 2025, the Company had accounts receivable of $7.3 million and $9.5 million, respectively, related to the Regeneron agreements. The Company had no deferred revenue as of June 30, 2026, and deferred revenue of $7.3 million as of December 31, 2025, related to the Regeneron agreements.

The Company has existing license and collaboration agreements with AvenCell Therapeutics, Inc. (“AvenCell”), Kyverna, and ONK Therapeutics, Ltd. (“ONK”). Since December 31, 2025, there have been no material changes to the key terms of the AvenCell, Kyverna and ONK license and collaboration agreements. The Company had no material revenue from these collaborations during the three and six months ended June 30, 2026 and 2025.